Annals of Surgical Oncology

, Volume 23, Issue 12, pp 3860–3869 | Cite as

Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1–2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy

  • Shih-Fan Lai
  • Yu-Hsuan Chen
  • Wen-Hung Kuo
  • Huang-Chun Lien
  • Ming-Yang Wang
  • Yen-Shen Lu
  • Chiao Lo
  • Sung-Hsin KuoEmail author
  • Ann-Lii Cheng
  • Chiun-Sheng HuangEmail author
Breast Oncology



Administering postmastectomy radiotherapy (PMRT) to patients with T1–2 breast cancer and one to three positive axillary lymph nodes (ALNs) is controversial. The current study assessed the association of clinicopathologic features and molecular subclassification with locoregional recurrence (LRR) in patients who did not receive PMRT.


Between January 2004 and December 2008, 293 patients with T1–2 breast cancer and one to three positive ALNs not receiving PMRT were analyzed. Most of the patients received an anthracycline- or taxane-based regimen or both. The patients were divided according to the four molecular subtypes as follows: luminal A/B, luminal human epidermal growth factor receptor 2 (HER2), HER2, and triple-negative breast cancer. Overall survival (OS) and LRR were calculated using the Kaplan–Meier method, and the clinicopathologic prognostic factors were compared using log-rank tests and the Cox regression model.


After a median follow-up period of 82.8 months, the 10-year LRR and OS were respectively 10 %, and 88.9 %. The patients with triple-negative breast cancer had a higher 5-year LRR rate (10.6 %) than those without this disease (4.2 %) (p = 0.05). Multivariate analysis showed that young age (≤40 years), tumor larger than 3 cm, and the presence of extensive intraductal components were significant risk factors for LRR. The 5-year LRR was 3.1 % for the patients without the aforementioned risk factors, 7.9 % for those with one risk factor, and 25 % for those with two or more risk factors (p < 0.001).


Administering modern systemic therapy to early breast cancer patients not receiving PMRT reduced the LRR rate. Younger patients, those with a tumor larger than 3 cm, and those with extensive intraductal components might benefit from PMRT.


Axillary Lymph Node Dissection Sentinel Lymph Node Dissection Extensive Intraductal Component Aforementioned Risk Factor Positive ALNs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors thank the Cancer Registry, Cancer Administration and Coordination Center, National Taiwan University Hospital for providing the necessary patient information. This study was supported by research Grants MOST 104-2314-B-002-189-MY3, 104-2811-B-002-058, and 104-2314-B-002-152-MY3 from the Ministry of Science and Technology, Taiwan, and Grants MOHW104-TD-B-111-04 and MOHW105-TDU-B-211-134005 from the Ministry of Health and Welfare, Taiwan.

Compliance with Ethical Standards

Conflict of Interest

There are no conflicts of interest.

Supplementary material

10434_2016_5435_MOESM1_ESM.docx (21 kb)
Supplementary material 1 (DOCX 20 kb)
10434_2016_5435_MOESM2_ESM.docx (22 kb)
Supplementary material 2 (DOCX 22 kb)
10434_2016_5435_MOESM3_ESM.docx (36 kb)
Supplementary material 3 (DOCX 35 kb)
10434_2016_5435_MOESM4_ESM.docx (15 kb)
Supplementary material 4 (DOCX 15 kb)
10434_2016_5435_MOESM5_ESM.tif (3.6 mb)
Supplementary material 5 (TIFF 3715 kb)


  1. 1.
    Early Breast Cancer Trialists’ Collaborative Group.Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome in 100,000 randomised women in 123 randomised trials. Lancet. 2012;379:432–44.CrossRefGoogle Scholar
  2. 2.
    Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–83.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.CrossRefGoogle Scholar
  4. 4.
    RechtA,EdgeSB,SolinLJ, et al. Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539–69.PubMedGoogle Scholar
  5. 5.
    Harris JR, Halpin-Murphy P, McNeese M, et al. Consensus statement on postmastectomy radiation therapy. Int J Radiat Oncol Biol Phys. 1999;44:989–90.CrossRefPubMedGoogle Scholar
  6. 6.
    MacDonald SM, Abi-Raad RF, Alm El-Din MA, et al. Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys. 2009;75:1297–303.CrossRefPubMedGoogle Scholar
  7. 7.
    Yang PS, Chen CM, Liu MC, et al. Radiotherapy can decrease locoregional recurrence and increase survival in mastectomy patients with T1 to T2 breast cancer and one to three positive nodes with negative estrogen receptor and positive lymphovascular invasion status. Int J Radiat Oncol Biol Phys. 2010;77:516–22.CrossRefPubMedGoogle Scholar
  8. 8.
    Sharma R, Bedrosian I, Lucci A, et al. Present-day locoregional control in patients with T1 or T2 breast cancer with 0–3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010;7:2899–908.CrossRefGoogle Scholar
  9. 9.
    Botteri E, Gentilini O, Rotmensz N, et al. Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution. Breast Cancer Res Treat. 2012;134:1221–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Tendulkar RD, Rehman S, Shukla ME, et al. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1–3 positive lymph nodes treated with modern systemic therapy. Int J Radiat Oncol Biol Phys. 2012; 83:577–81.CrossRefGoogle Scholar
  11. 11.
    McBride A, Allen P, Woodward W, et al. Locoregional recurrence risk for patients with T1, 2 breast cancer with 1–3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014;89:392–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Cosar R, Uzal C, Tokatli F, et al. Postmastectomy irradiation in breast in breast cancer patients with T1–2 and 1–3 positive axillary lymph nodes: is there a role for radiation therapy? Radiat Oncol. 2011;6:28.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Greenbaum MP, Strom EA, Allen PK, et al. Low locoregional recurrence rates in patients treated after 2000 with doxorubicin based chemotherapy, modified radical mastectomy, and postmastectomy radiation. Radiother Oncol. 2010;95:312–6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Kuo SH, Lien HC, You SL, et al. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I–II and operable stage III Taiwanese breast cancer patients. Breast. 2008;17:646–53.CrossRefPubMedGoogle Scholar
  15. 15.
    Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol. 2009;27:1323–33.CrossRefPubMedGoogle Scholar
  17. 17.
    Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25:2127–32.CrossRefPubMedGoogle Scholar
  18. 18.
    Shah AR, Glazebrook KN, Boughey JC, et al. Does BMI affect the accuracy of preoperative axillary ultrasound in breast cancer patients? Ann Surg Oncol. 2014;21:3278–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Cools-Lartigue J, Sinclair A, Trabulsi N, et al. Preoperative axillary ultrasound and fine-needle aspiration biopsy in the diagnosis of axillary metastases in patients with breast cancer: predictors of accuracy and future implications. Ann Surg Oncol. 2013;20:819–27.CrossRefPubMedGoogle Scholar
  20. 20.
    Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol. 2006;24:2268–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Nielsen HM, Overgaard M, Grau C, et al. Locoregional recurrence after mastectomy in high-risk breast cancer—risk and prognosis: an analysis of patients from the DBCG 82 b & c randomization trials. Radiother Oncol. 2006;79:147–55.CrossRefPubMedGoogle Scholar
  22. 22.
    Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b & c randomized trials. Radiother Oncol. 2007;82:247–53.CrossRefPubMedGoogle Scholar
  23. 23.
    Taghian A, Jeong JH, Mamounas E, et al. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004;22:4247–54.CrossRefPubMedGoogle Scholar
  24. 24.
    Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353:1641–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Huo D, Hou N, Jaskowiak N, et al. Use of postmastectomy radiotherapy and survival rates for breast cancer patients with T1–T2 and one to three positive lymph nodes. Ann Surg Oncol. 2015;22,4295–304.CrossRefPubMedGoogle Scholar
  26. 26.
    Olivotto IA, Truong PT, Chua B. Postmastectomy radiation therapy: who needs it? J Clin Oncol. 2004;22:4237–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Taylor ME, Haffty BG, Rabinovitch R, et al. ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast. Int J Radiat Oncol Biol Phys. 2009;73:997–1002.CrossRefPubMedGoogle Scholar
  28. 28.
    Moo TA, McMillan R, Lee M, et al. Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1–T2 breast cancer and 1–3 positive lymph nodes. Ann Surg Oncol. 2014;21:1569–74.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hamamoto Y, Ohsumi S, Aogi K, et al. Are there high-risk subgroups for isolated locoregional failure in patients who had T1/2 breast cancer with one to three positive lymph nodes and received mastectomy without radiotherapy? Breast Cancer. 2014;21:177–82.CrossRefPubMedGoogle Scholar
  30. 30.
    Cheng SH, Tsai SY, Yu BL, et al. Validating a prognostic scoring system for postmastectomy locoregional recurrence in breast cancer. Int J Radiat Oncol Biol Phys. 2013;85:953–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Kyndi M, Sorensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26:1419–26.CrossRefPubMedGoogle Scholar
  32. 32.
    Truong PT, Woodward WA, Thames HD, et al. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1–3 positive nodes: an analysis of prospective data from British Columbia and the M.D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 2007;68:59–65.CrossRefPubMedGoogle Scholar
  33. 33.
    Mukesh MB, Duke S, Parashar D, et al. The Cambridge postmastectomy radiotherapy (C-PMRT) index: a practical tool for patient selection. Radiother Oncol. 2014;110:461–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393–8.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Millar EK, Graham PH, O’Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel. J Clin Oncol. 2009;27:4701–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–502.CrossRefPubMedGoogle Scholar
  37. 37.
    Telli M. Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. Am Soc Clin Oncol Educ Book. 2014:e37–42.Google Scholar
  38. 38.
    Kyndi M, Sørensen FB, Knudsen H, et al. Estrogen receptor, progesterone receptor, HER2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:1419–26.CrossRefPubMedGoogle Scholar
  39. 39.
    Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011;29:2852–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Kuo SH, Huang CS, Kuo WH, et al. Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence. Int J Radiat Oncol Biol Phys. 2008;72:1456–64.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Shih-Fan Lai
    • 1
    • 2
  • Yu-Hsuan Chen
    • 2
  • Wen-Hung Kuo
    • 3
  • Huang-Chun Lien
    • 4
  • Ming-Yang Wang
    • 3
  • Yen-Shen Lu
    • 2
    • 5
  • Chiao Lo
    • 3
  • Sung-Hsin Kuo
    • 2
    • 5
    • 6
    Email author
  • Ann-Lii Cheng
    • 2
    • 5
    • 6
  • Chiun-Sheng Huang
    • 3
    Email author
  1. 1.Division of Radiation Oncology, Department of Medical ImagingNational Taiwan University HospitalHsin-Chu CityTaiwan
  2. 2.Division of Radiation Oncology, Department of OncologyNational Taiwan University Hospital and National Taiwan University Cancer CenterTaipeiTaiwan
  3. 3.Department of SurgeryNational Taiwan University Hospital and National Taiwan University Cancer CenterTaipeiTaiwan
  4. 4.Department of PathologyNational Taiwan University Hospital and National Taiwan University Cancer CenterTaipeiTaiwan
  5. 5.Cancer Research CenterNational Taiwan University College of MedicineTaipeiTaiwan
  6. 6.Graduate Institute of OncologyNational Taiwan University College of MedicineTaipeiTaiwan

Personalised recommendations